Hepatopathy of unknown etiology – is liver biopsy a good tool in differential diagnosis?

Abstract

IntroductionLiver biopsy is a well-known method for the diagnosis and evaluation of chronic diffuse liver diseases, especially among patients with “hepatopathy of unknown origin”.Material and methodsIn the years 2014–2015 we performed 259 liver biopsies in 28 patients (22 females, 6 males, aged 18–65 years, mean: 45 years) with an initial diagnosis of “hepatopathy of unknown origin”. The liver biopsies of these 28 patients were revised by two independent pathologists.ResultsHistopathological features of autoimmune conditions were found in 11 cases, steatohepatitis with/without Mallory bodies in 7, simple steatosis without inflammation in 2 cases. In the other 8 cases the histopathological features were non-specific but pointed to vanishing bile duct syndrome, hemochromatosis, acute inflammation or fibrosis without inflammation. Surprisingly, only mild fibrosis without inflammatory infiltrates was present in one patient with a high titer of antinuclear antibodies (ANA > 1 : 3200). Mild cholestasis with bilirubinostasis was found in 4 cases. One patient had prominent lobular iron deposits and is now under observation for hemochromatosis. Vanishing bile duct syndrome as ductopenia without any signs of inflammation was found in one patient with suspicion of primary biliary cirrhosis. In one liver biopsy specimen we found normal liver architecture without inflammation or steatosis in a patient with elevated ALT and GGT, negative for viral antibodies and autoantibodies.ConclusionsLiver biopsy – despite the increasing access to new, non-invasive methods – remains a useful method in the differential diagnosis of liver diseases.

A Nomogram Predicting the Prognosis of Children With Biliary Atresia After Hepatoportoenterostomy

“…Liver biopsy is not safe for BA children and the obtained histological material is insufficient although it is the gold standard for fibrosis ( 10 ). Liver stiffness measurement (LSM), obtained by shear wave elastography (SWE) has become a reliable and popular non-invasive means in assessing hepatic fibrosis, which has been used for the differential diagnosis of BA ( 11 – 13 ). At present, elastography is applied in the post-KPE follow-up in some studies, and their LSM values correlate well with the histological stage of liver fibrosis, indicating good performance in the assessment of postoperative liver fibrosis ( 14 , 15 ).…”

Novel Alhagi maurorum leaves mediated synthesis of titanium nanoparticles for human breast carcinoma applications: a preclinical trial study

“…In people whose cancer has spread to other body parts, treatments are mainly aimed at improving the quality of life and comfort of the person [2,3]. Raloxifene or tamoxifen can be administered to inhibit human breast cancer in people who are more likely to get it [5][6][7][8][9]. Chemotherapeutic drugs have severe side effects for the patients, so finding new formulations with low side effects are the priority of the Food and Drug Administration.…”

“…Chemotherapeutic drugs have severe side effects for the patients, so finding new formulations with low side effects are the priority of the Food and Drug Administration. Previous reports have revealed that metallic nanocomposites have unique anticancer efficacies with low side effects [5][6][7][8][9][10].…”

Novel green synthesis of silver nanoparticles mediated by <i>Curcumae kwangsiensis</i> for anti-lung cancer activities: a preclinical trial study

“…The main anti-human lung cancer chemotherapeutic supplements/drugs are alectinib, ceritinib, crizotinib, and brigatinib [5]. Due to severe side effects of the chemotherapeutic drugs and supplements, the formulation of the chemotherapeutic medications from Ag nanoparticles are the research priority of pharmacology, oncology, and organic chemistry researchers [6][7][8][9][10].…”